SEARCH

SEARCH BY CITATION

References

  • 1
    Morris A, Lundgren JD, Masur H et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10: 17131720.
  • 2
    Mansharamani N, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of hiv-associated cases to other immunocompromised states. Chest 2000; 118: 704711.
  • 3
    Limper A, Offord K, Smith T, Martin W. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without aids. Am Rev Respir Dis 1989; 140: 12041209.
  • 4
    Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J. Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009; 135: 655661.
  • 5
    Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 2008; 197: 1017.
  • 6
    Jiancheng W, Minjun H, Yi-jun A et al. Screening Pneumocystis carinii pneumonia in non-HIV-infected immunocompromised patients using polymerase chain reaction. Diagn Microbiol Infect Dis 2009; 64: 396401.
  • 7
    Larsen HH, Masur H, Kovacs JA et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol 2002; 40: 490494.
  • 8
    Huggett JF, Taylor MS, Kocjan G et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax 2008; 63: 154159.
  • 9
    Alanio A, Desoubeaux G, Sarfati C et al. Real-time PCR assay-based strategy for differentiation between active Peumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 2011 [Epub ahead of print].
  • 10
    Flori P, Bellete B, Durand F et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 2004; 53: 603607.
  • 11
    Larsen HH, Huang L, Kovacs JA et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis 2004; 189: 16791683.
  • 12
    Fillaux J, Malvy S, Alvarez M et al. Accuracy of a routine real-time PCR assay for the diagnosis of Pneumocystis jirovecii pneumonia. J Microbiol Methods 2008; 75: 258261.
  • 13
    Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 2006; 16: 282288.
  • 14
    de Boer MG, Gelinck LB, van Zelst BD et al. β-d-glucan and s-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect 2011; 62: 93100.
  • 15
    Nakamura H, Tateyama M, Tasato D et al. Clinical utility of serum beta-d-glucan and kl-6 levels in Pneumocystis jirovecii pneumonia. Intern Med 2009; 48: 195202.
  • 16
    Tasaka S, Hasegawa N, Kobayashi S et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007; 131: 11731180.
  • 17
    Damiani C, Le Gal S, Lejeune D et al. Serum (1[RIGHTWARDS ARROW]3)-β-d-glucan levels in primary infection and pulmonary colonization with Pneumocystis jirovecii. J Clin Microbiol 2011; 49: 20002002.
  • 18
    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837845.
  • 19
    Lundgren B, Wakefield AE. PCR for detecting Pneumocystis carinii in clinical or environmental samples. FEMS Immunol Med Microbiol 1998; 22: 97101.
  • 20
    Desmet S, Van Wijngaerden E, Maertens J et al. Serum (1-3)-beta-d-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 2009; 47: 38713874.
  • 21
    Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1[RIGHTWARDS ARROW]3)-beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008; 46: 10091013.
  • 22
    Watanabe T, Yasuoka A, Tanuma J et al. Serum (1[RIGHTWARDS ARROW]3) beta-d-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with aids. Clin Infect Dis 2009; 49: 11281131.
  • 23
    Del Bono V, Mularoni A, Furfaro E et al. Clinical evaluation of a (1,3)-beta-d-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol 2009; 16: 15241526.
  • 24
    Mennink-Kersten MA, Warris A, Verweij PE. 1,3-β-d-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354: 28342835.
  • 25
    Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-β-d-glucan assay reactivity. Clin Infect Dis 2008; 46: 19301931.
  • 26
    Procop GW, Haddad S, Quinn J et al. Detection of Pneumocystis jiroveci in respiratory specimens by four staining methods. J Clin Microbiol 2004; 42: 33333335.